Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 11,460,000 shares, a decrease of 5.4% from the September 30th total of 12,110,000 shares. Approximately 8.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,320,000 shares, the days-to-cover ratio is currently 8.7 days.
Halozyme Therapeutics Price Performance
Shares of HALO stock opened at $47.81 on Tuesday. The stock has a 50 day moving average of $41.99 and a two-hundred day moving average of $43.94. The company has a current ratio of 2.72, a quick ratio of 2.23 and a debt-to-equity ratio of 3.91. Halozyme Therapeutics has a 12 month low of $31.36 and a 12 month high of $52.98. The company has a market capitalization of $6.59 billion, a P/E ratio of 18.90, a P/E/G ratio of 0.81 and a beta of 1.18.
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.47 by $0.03. The business had revenue of $152.37 million during the quarter, compared to the consensus estimate of $156.00 million. Halozyme Therapeutics had a return on equity of 101.73% and a net margin of 75.11%. Halozyme Therapeutics’s revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. As a group, equities analysts expect that Halozyme Therapeutics will post 1.93 EPS for the current year.
Hedge Funds Weigh In On Halozyme Therapeutics
Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC raised its position in shares of Halozyme Therapeutics by 66.6% during the third quarter. SG Americas Securities LLC now owns 66,233 shares of the biopharmaceutical company’s stock worth $2,619,000 after acquiring an additional 26,479 shares during the last quarter. Comerica Bank grew its stake in Halozyme Therapeutics by 2.1% in the third quarter. Comerica Bank now owns 64,525 shares of the biopharmaceutical company’s stock valued at $3,005,000 after acquiring an additional 1,333 shares during the period. US Bancorp DE grew its stake in Halozyme Therapeutics by 2.1% in the third quarter. US Bancorp DE now owns 11,305 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 236 shares during the period. Synovus Financial Corp grew its stake in Halozyme Therapeutics by 43.7% in the third quarter. Synovus Financial Corp now owns 76,918 shares of the biopharmaceutical company’s stock valued at $3,040,000 after acquiring an additional 23,393 shares during the period. Finally, Strs Ohio grew its stake in Halozyme Therapeutics by 65.4% in the third quarter. Strs Ohio now owns 44,000 shares of the biopharmaceutical company’s stock valued at $1,739,000 after acquiring an additional 17,400 shares during the period. Institutional investors own 91.72% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on HALO. StockNews.com began coverage on Halozyme Therapeutics in a report on Wednesday, October 12th. They set a “hold” rating for the company. Morgan Stanley began coverage on Halozyme Therapeutics in a research report on Friday, September 9th. They set an “overweight” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.00.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Halozyme Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Halozyme Therapeutics wasn’t on the list.
While Halozyme Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Down 5.4% in October